Anteris Technologies Global Stock Drops 5.8%

Analysts Weigh In on Whether Investors Should Sell

Apr. 6, 2026 at 8:14pm

Got story updates? Submit your updates here. ›

An extreme close-up of a complex array of gears, levers, and metal components, representing the complex financial infrastructure behind Anteris Technologies Global's stock performance.The inner workings of Anteris Technologies Global's financial machinery reflect the volatility and uncertainty surrounding the medical device company's stock price.Eagan Today

Shares of Anteris Technologies Global (NASDAQ:AVR) fell 5.8% during trading on Monday, with the stock closing at $5.18 per share. The company's stock has seen significant volatility, with a 52-week range of $4.50 to $7.25. Several research analysts have issued reports on the stock, with mixed ratings and price targets.

Why it matters

Anteris Technologies Global is a medical device company focused on developing solutions for heart diseases. The stock's performance is closely watched by investors as an indicator of the company's financial health and growth potential. A significant drop in the stock price could raise concerns about the company's outlook and impact investor confidence.

The details

The 5.8% decline in Anteris Technologies Global's stock price on Monday was attributed to a broader market sell-off. The company's stock has been trading in a range of $4.50 to $7.25 over the past 52 weeks. Several research analysts have weighed in on the stock, with Cantor Fitzgerald and Lake Street Capital maintaining 'overweight' ratings and $15 price targets. However, Weiss Ratings has issued a 'sell (e+)' rating on the stock.

  • Anteris Technologies Global's stock closed at $5.50 on the previous trading day.
  • The stock traded as low as $5.21 on Monday before closing at $5.18.

The players

Anteris Technologies Global

A medical device company focused on developing solutions for heart diseases. The company is headquartered in Eagan, Minnesota.

Cantor Fitzgerald

A financial services firm that has issued an 'overweight' rating and $15 price target on Anteris Technologies Global's stock.

Lake Street Capital

An investment firm that has also issued an 'overweight' rating and $15 price target on Anteris Technologies Global's stock.

Weiss Ratings

A research firm that has issued a 'sell (e+)' rating on Anteris Technologies Global's stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The drop in Anteris Technologies Global's stock price highlights the volatility and uncertainty surrounding the company's outlook. While some analysts remain optimistic, the mixed ratings and price targets suggest that investors should closely monitor the company's performance and developments in the medical device industry.